Ishita Drugs and Industries Past Earnings Performance
Past criteria checks 5/6
Ishita Drugs and Industries has been growing earnings at an average annual rate of 7%, while the Pharmaceuticals industry saw earnings growing at 15.2% annually. Revenues have been growing at an average rate of 1.1% per year. Ishita Drugs and Industries's return on equity is 7.6%, and it has net margins of 5%.
Key information
7.0%
Earnings growth rate
7.0%
EPS growth rate
| Pharmaceuticals Industry Growth | 17.5% |
| Revenue growth rate | 1.1% |
| Return on equity | 7.6% |
| Net Margin | 5.0% |
| Last Earnings Update | 30 Jun 2024 |
Recent past performance updates
Recent updates
Revenue & Expenses Breakdown
How Ishita Drugs and Industries makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Jun 24 | 151 | 8 | 14 | 0 |
| 31 Mar 24 | 152 | 7 | 13 | 0 |
| 31 Dec 23 | 133 | 6 | 14 | 0 |
| 30 Sep 23 | 134 | 6 | 14 | 0 |
| 30 Jun 23 | 118 | 5 | 13 | 0 |
| 31 Mar 23 | 121 | 6 | 13 | 0 |
| 31 Dec 22 | 134 | 8 | 13 | 0 |
| 30 Sep 22 | 145 | 8 | 12 | 0 |
| 30 Jun 22 | 146 | 8 | 12 | 0 |
| 31 Mar 22 | 141 | 8 | 12 | 0 |
| 31 Dec 21 | 141 | 9 | 11 | 0 |
| 30 Sep 21 | 136 | 9 | 11 | 0 |
| 30 Jun 21 | 145 | 9 | 11 | 0 |
| 31 Mar 21 | 139 | 8 | 11 | 0 |
| 31 Dec 20 | 133 | 6 | 11 | 0 |
| 30 Sep 20 | 135 | 5 | 11 | 0 |
| 30 Jun 20 | 133 | 5 | 11 | 0 |
| 31 Mar 20 | 148 | 5 | 11 | 0 |
| 31 Dec 19 | 144 | 5 | 11 | 0 |
| 30 Sep 19 | 127 | 4 | 11 | 0 |
| 30 Jun 19 | 112 | 4 | 10 | 0 |
| 31 Mar 19 | 91 | 4 | 10 | 0 |
| 31 Dec 18 | 83 | 3 | 9 | 0 |
| 30 Sep 18 | 72 | 3 | 8 | 0 |
| 30 Jun 18 | 71 | 3 | 8 | 0 |
| 31 Mar 18 | 68 | 2 | 8 | 0 |
| 31 Dec 17 | 61 | 2 | 8 | 0 |
| 30 Sep 17 | 67 | 2 | 8 | 0 |
| 30 Jun 17 | 57 | 2 | 9 | 0 |
| 31 Mar 17 | 58 | 2 | 7 | 0 |
| 31 Dec 16 | 57 | 2 | 7 | 0 |
| 30 Sep 16 | 58 | 2 | 7 | 0 |
| 30 Jun 16 | 67 | 1 | 0 | 0 |
| 31 Mar 16 | 65 | 1 | 7 | 0 |
| 31 Dec 15 | 61 | 2 | 11 | 0 |
| 30 Sep 15 | 63 | 2 | 11 | 0 |
| 30 Jun 15 | 74 | 2 | 11 | 0 |
| 31 Mar 15 | 70 | 2 | 7 | 0 |
| 31 Dec 14 | 66 | 2 | 11 | 0 |
| 30 Sep 14 | 60 | 1 | 11 | 0 |
| 30 Jun 14 | 64 | 1 | 6 | 0 |
| 31 Mar 14 | 67 | 2 | 11 | 0 |
| 31 Dec 13 | 99 | 3 | 6 | 0 |
Quality Earnings: 524400 has high quality earnings.
Growing Profit Margin: 524400's current net profit margins (5%) are higher than last year (4.6%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 524400's earnings have grown by 7% per year over the past 5 years.
Accelerating Growth: 524400's earnings growth over the past year (38.3%) exceeds its 5-year average (7% per year).
Earnings vs Industry: 524400 earnings growth over the past year (38.3%) exceeded the Pharmaceuticals industry 19.2%.
Return on Equity
High ROE: 524400's Return on Equity (7.6%) is considered low.